<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00876213</url>
  </required_header>
  <id_info>
    <org_study_id>KA-20060095</org_study_id>
    <nct_id>NCT00876213</nct_id>
  </id_info>
  <brief_title>Amylin and Glucagon-Like Peptide-1 (GLP-1): Influence on Gastric Emptying, Appetite and Food Intake in Humans</brief_title>
  <official_title>Amylin and GLP-1: Influence on Gastric Emptying, Appetite and Food Intake in Humans.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hvidovre University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amylin Pharmaceuticals, LLC.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hvidovre University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this proposal is to dissect the mechanisms controlling gastric emptying, appetite&#xD;
      and food intake in humans, and to obtain new knowledge to fight obesity on a pharmacological&#xD;
      basis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of the present study is to elucidate the mechanisms behind the effects of&#xD;
      glucagon-like peptide-1 (GLP-1) on gastric emptying, appetite and food intake. The first&#xD;
      GLP-1 based anti-diabetic therapy was approved by the FDA in 2005 and is now on the market in&#xD;
      the United States. The strong glucose-dependent insulinotropic property of GLP-1 is a highly&#xD;
      attractive feature in the pursue of optimal glycaemic control in type 2 diabetes. Moreover,&#xD;
      the potential of GLP-1 to reduce gastric emptying, appetite and food intake makes it an&#xD;
      attractive tool in the fight against obesity, a pandemic condition that often leads to type 2&#xD;
      diabetes, and several companies are developing weight lowering drugs based on GLP-1.&#xD;
      Interestingly, another peptide, amylin, exerts very similar effects on gastric emptying,&#xD;
      appetite and food intake in humans. Amylin is found in insulin-rich granules in pancreatic&#xD;
      beta-cells and is co-secreted with insulin upon insulinotropic stimuli. Currently, it is not&#xD;
      known whether the inhibiting effects of GLP-1 on gastric emptying, appetite and food intake&#xD;
      are directly mediated by GLP-1, or if the effects are secondary to the robust insulin&#xD;
      responses, and thereby amylin responses, elicited by GLP-1. The objective of the present&#xD;
      study is therefore to further elucidate the mechanisms of these effects in order to&#xD;
      strengthen the development of anti-diabetic drugs with potential weight lowering&#xD;
      capabilities.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
  </study_design_info>
  <enrollment type="Actual">23</enrollment>
  <condition>Diabetes</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with type 1 diabetes and matched healthy control subjects&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with type 1 diabetes&#xD;
&#xD;
               -  Informed oral and written consent&#xD;
&#xD;
               -  Caucasians over the age of 18 years with type 1 diabetes (diagnosed according to&#xD;
                  the criteria of WHO) receiving long acting insulin&#xD;
&#xD;
               -  C-peptide negative glucagon test&#xD;
&#xD;
               -  Normal blood haemoglobin concentration&#xD;
&#xD;
          -  Healthy control subjects&#xD;
&#xD;
               -  Informed oral and written consent&#xD;
&#xD;
               -  Caucasians over the age of 18 years&#xD;
&#xD;
               -  Normal 75 g- oral glucose tolerance test (OGTT) according to the criteria of WHO&#xD;
&#xD;
               -  Negative islet cell autoantibodies (ICA) and GAD-65 autoantibodies&#xD;
&#xD;
               -  No first-degree relatives with diabetes&#xD;
&#xD;
               -  Normal blood haemoglobin concentration&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with type 1 diabetes&#xD;
&#xD;
               -  Residual beta-cell function (evaluated with glucagon test)&#xD;
&#xD;
               -  Impaired hepatic function (aspartate aminotransferase (ASAT) and/or alanine&#xD;
                  aminotransferase (ALAT) &gt; 2 times upper normal limit)&#xD;
&#xD;
               -  Diabetic nephropathy (serum-creatinine &gt; 130 µM and/or albuminuria)&#xD;
&#xD;
               -  Diabetic neuropathy&#xD;
&#xD;
               -  Proliferative diabetic retinopathy&#xD;
&#xD;
               -  Pregnancy, breastfeeding or intention of becoming pregnant or judged to be using&#xD;
                  inadequate contraceptive measures&#xD;
&#xD;
          -  Healthy control subjects&#xD;
&#xD;
               -  Impaired hepatic function (ASAT or ALAT &gt; 2 times upper normal limit)&#xD;
&#xD;
               -  Impaired renal function (serum-creatinine &gt; 130 μM and/or albuminuria)&#xD;
&#xD;
               -  First-degree relatives with diabetes&#xD;
&#xD;
               -  Pregnancy, breastfeeding or intention of becoming pregnant or judged to be using&#xD;
                  inadequate contraceptive measures&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Meena Asmar, MD,Ph.Dstud.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Panum Institut</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jens Juul Holst, Professor,MD</last_name>
    <role>Study Director</role>
    <affiliation>Panum Institut</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hvidovre Hospital</name>
      <address>
        <city>Hvidovre</city>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>April 2009</verification_date>
  <study_first_submitted>April 3, 2009</study_first_submitted>
  <study_first_submitted_qc>April 3, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2009</study_first_posted>
  <last_update_submitted>April 3, 2009</last_update_submitted>
  <last_update_submitted_qc>April 3, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 6, 2009</last_update_posted>
  <responsible_party>
    <name_title>University of Copenhagen</name_title>
    <organization>University of Copenhagen</organization>
  </responsible_party>
  <keyword>Amylin</keyword>
  <keyword>GLP-1</keyword>
  <keyword>gastric emptying</keyword>
  <keyword>appetite and food intake</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

